Table 1.
Patient demographics (N = 1,074)
| Characteristic No. | Radiotherapy alone n = 253 | CCRT n = 502 | Chemotherapy alone n = 319 | p value |
|---|---|---|---|---|
| Year | <0.001 | |||
| 2004 | 78 (30.8%) | 77 (15.3%) | 48 (15.0%) | |
| 2005 | 66 (26.1%) | 107 (21.3%) | 52 (16.3%) | |
| 2006 | 44 (17.4%) | 95 (18.9%) | 67 (21.0%) | |
| 2007 | 36 (14.2%) | 111 (22.1%) | 79 (24.8%) | |
| 2008 | 29 (11.5%) | 112 (22.3%) | 73 (22.9%) | |
| Age | 49.4 (±12.2) | 48.1 (±11.9) | 46.7 (±11.8) | 0.024 |
| Clinical stage | 0.65 | |||
| IB1 | 111 (43.9%) | 199 (39.6%) | 141 (44.2%) | |
| IB2 | 39 (15.4%) | 95 (18.9%) | 61 (19.1%) | |
| IIA | 28 (11.1%) | 64 (12.7%) | 34 (10.7%) | |
| IIB | 75 (29.6%) | 144 (28.7%) | 83 (26.0%) | |
| Histology | <0.001 | |||
| Squamous | 215 (85.0%) | 382 (76.1%) | 156 (48.9%) | |
| Adenocarcinoma | 21 (8.3%) | 94 (18.7%) | 109 (34.2%) | |
| Adenosquamous | 15 (5.9%) | 24 (4.8%) | 40 (12.5%) | |
| Others | 2 (0.8%) | 2 (0.4%) | 14 (4.4%) | |
| Parametrium | 0.06 | |||
| Not involved | 142 (56.1%) | 289 (57.6%) | 207 (64.9%) | |
| Involved | 111 (43.9%) | 213 (42.4%) | 112 (35.1%) | |
| Deep stromal invasion | 0.08 | |||
| No | 38 (17.6%) | 99 (21.9%) | 44 (15.4%) | |
| Yes | 178 (82.4%) | 353 (78.1%) | 241 (84.6%) | |
| Tumor size | 0.58 | |||
| ≤2.0 cm | 31 (12.7%) | 66 (13.7%) | 39 (12.7%) | |
| 2.1–4.0 cm | 119 (48.8%) | 227 (47.2%) | 158 (51.3%) | |
| 4.1–6.0 cm | 84 (34.4%) | 153 (31.8%) | 90 (29.2%) | |
| >6.0 cm | 10 (4.1%) | 35 (7.3%) | 21 (6.8%) | |
| LVSI | 0.60 | |||
| Not present | 25 (10.7%) | 57 (11.9%) | 42 (13.5%) | |
| Present | 209 (89.3%) | 424 (88.1%) | 270 (86.5%) | |
| Uterine corpus | 0.001 | |||
| Not involved | 192 (76.2%) | 412 (82.4%) | 218 (71.5%) | |
| Involved | 60 (23.8%) | 88 (17.6%) | 87 (28.5%) | |
| Pelvic washing | 0.06 | |||
| No malignancy | 136 (92.5%) | 240 (93.0%) | 173 (86.9%) | |
| Malignancy | 11 (7.5%) | 18 (7.0%) | 26 (13.1%) | |
| Ovary | <0.001 | |||
| Not involved | 243 (98.0%) | 488 (98.2%) | 275 (93.2%) | |
| Involved | 5 (2.0%) | 9 (1.8%) | 20 (6.8%) | |
| Pelvic lymph nodes | 36 (22) | 31 (20) | 33 (21) | 0.47 |
| Not involved | 0 | 2 (0.4%) | 2 (0.6%) | |
| Involved | 253 (100%) | 500 (99.6%) | 317 (99.4%) | |
| Para-aortic lymph nodes | 9 (11) | 7 (10) | 14 (17) | 0.003 |
| Not involved | 59 (85.5%) | 76 (75.2%) | 58 (61.7%) | |
| Involved | 10 (14.5%) | 25 (24.8%) | 36 (38.3%) | |
| Lymph node ratio (%) | ||||
| Pelvic | 5.0 (7.2) | 7.1 (8.8) | 7.1 (10.7) | <0.001 |
| Para-aortic | 66.7 (52.2) | 23.2 (82.2) | 31.0 (40.7) | 0.015 |
| Additional radiotherapy | ||||
| Aortic boost | <0.001 | |||
| No | 221 (87.4%) | 428 (85.3%) | 319 (100%) | |
| Yes | 32 (12.6%) | 74 (14.7%) | 0 | |
| Vaginal brachytherapy | <0.001 | |||
| No | 208 (85.6%) | 401 (83.9%) | 256 (97.3%) | |
| Yes | 35 (14.4%) | 77 (16.1%) | 7 (2.7%) |
Mean (±SD), median (interquartile range), or number (%) per column are shown. Abbreviations: CCRT, concurrent chemoradiotherapy; LVSI, lymphovascular space invasion.